Upcoming Deadline for Sage Therapeutics Investors
If you hold stocks in Sage Therapeutics, Inc., it’s important to be aware of an imminent deadline. The Law Offices of Howard G. Smith is notifying all affected investors about the need to file a lead plaintiff motion. If you bought shares of Sage Therapeutics, Inc. (NASDAQ: SAGE) during the specified Class Period, it’s time to explore your legal options.
What You Need to Know About the Class Period
The relevant timeframe for this class action stretches from April 12, 2021, to July 23, 2024. If you owned Sage stocks during these dates, you may have been affected by significant events tied to the company’s product approvals and clinical trials.
Recent Events Affecting Sage’s Stock
Recent communications from Sage Therapeutics have led to major fluctuations in stock prices, raising concerns among investors. A key event occurred on August 4, 2023, when the U.S. Food and Drug Administration (FDA) made a notable announcement. They approved the New Drug Application (NDA) for zuranolone, but only for treating postpartum depression (PPD) in adults. Unfortunately, they also issued a Complete Response Letter for the major depressive disorder (MDD) treatment, stating that the application lacked enough evidence for effectiveness.
This news caused Sage’s stock to fall sharply, dropping by $19.35, which is a significant 53.6% decline, and it closed at $16.75 per share just a few days later, on August 7, 2023. This drastic loss undoubtedly impacted many investors negatively.
Additional Challenges and Investor Rights
Things took a turn for the worse on April 17, 2024, when Sage disclosed unfavorable results from a Phase 2 study regarding SAGE-718, aimed at addressing mild cognitive impairment due to Parkinson's Disease. The study failed to meet its primary goals of demonstrating sufficient effectiveness, resulting in another noticeable drop in the stock price, which closed at $12.57 per share after a decline of $3.06 or around 19.6%.
Moreover, the aftermath of a Phase 2 study for Sage-324, released on July 24, 2024, showed similarly disappointing results, leading to a further decline in stock value by $2.70; it ultimately closed at $10.38 per share. Such developments have contributed to a decline in investor confidence and trust.
Class Action Details and Your Rights
The class action claims that Sage Therapeutics and key figures within the company misled investors through significant omissions and false statements regarding the effectiveness and approval outlook of their products. This includes false assurances regarding the efficacy of zuranolone and misleading predictions about Sage-718 and Sage-324.
If you purchased or acquired shares of Sage during the indicated Class Period, you’re eligible to pursue representation in this class action lawsuit. While it’s crucial to act, immediate action isn't necessary. You can either decide to seek legal counsel or choose to remain a passive class member without taking further steps. Remember, the deadline to file your lead plaintiff motion is on October 28, 2024, so it’s important to stay informed about ongoing developments.
Getting Legal Help
The Law Offices of Howard G. Smith encourage investors to reach out for more details about their rights and how to navigate this situation. You can directly contact the firm at (215) 638-4847. Their team is prepared to assist investors in dealing with this complicated legal environment.
Frequently Asked Questions
What is the purpose of the class action lawsuit against Sage Therapeutics?
The class action lawsuit aims to address investor grievances about misleading statements from Sage Therapeutics that influenced stock prices during the Class Period.
How has Sage Therapeutics' stock performed recently?
Sage’s stock has experienced severe fluctuations due to regulatory announcements and disappointing clinical trial outcomes, leading to significant losses for investors.
When is the deadline to file a lead plaintiff motion?
The deadline to submit a lead plaintiff motion as part of the class action is October 28, 2024.
How can I participate in the class action lawsuit?
You can participate in the class action by hiring legal representation or taking no immediate action to remain a part of the suit.
Who can I contact for more information about my options?
The Law Offices of Howard G. Smith are available to answer questions, providing insights on legal rights and options for affected investors.
